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chronic traumatic encephalopathy in a boxer
Helen Ling1,2,3, Eleanna Kara2, Tamas Revesz1,2,3, Andrew J Lees1,2,3, Gordon T Plant4, Davide Martino5,6,
Henry Houlden2, John Hardy1,2,3 and Janice L Holton1,2,3,4*Abstract
We report the case of a 75-year-old ex-professional boxer who developed diplopia and eye movement abnormalities
in his 60’s followed by memory impairment, low mood and recurrent falls. Examination shortly before death revealed
hypomimia, dysarthria, vertical supranuclear gaze palsy and impaired postural reflexes. Pathological examination
demonstrated 4-repeat tau neuronal and glial lesions, including tufted astrocytes, consistent with a diagnosis of
progressive supranuclear palsy. In addition, neurofibrillary tangles composed of mixed 3-repeat and 4-repeat tau and
astrocytic tangles in a distribution highly suggestive of chronic traumatic encephalopathy were observed together with
limbic TDP-43 pathology. Possible mechanisms for the co-occurrence of these two tau pathologies are discussed.
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Chronic traumatic encephalopathy (CTE), previously
known as punch-drunk syndrome or dementia pugilistica,
is a neurodegenerative tauopathy caused by repetitive and
cumulative head trauma. CTE was first described in
boxers [1] but can occur in other contact sports, such as
steeplechase racing [2] and American football, and has
also been described in people who have been repeatedly
battered [3]. Pathological findings include generalized cor-
tical atrophy, cavum septum pellucidum, extensive neuro-
fibrillary tangles (NFTs) and astrocytic tangles composed
of mixed 3-repeat (3R) and 4-repeat (4R) tau isoforms in
the frontal and temporal cortices, often patchy and irregu-
lar, with predilection for perivascular regions [4] and in
the depths of cerebral sulci with NFTs in the limbic re-
gions, diencephalon and brainstem [5] but, in contrast to
Alzheimer’s disease (AD), there is relatively little amyloid-
β deposition (Aβ) [4-7].
PSP is a distinctive clinicopathological entity with estab-
lished neuropathological diagnostic criteria [8-11]. PSP* Correspondence: Janice.holton@ucl.ac.uk
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unless otherwise stated.presents classically with postural instability and falls,
slurred speech, a vertical supranuclear gaze palsy and a
dysexecutive syndrome [12], but there are a number of
well delineated atypical presentations [13-15].
We present the case of a retired professional boxer,
who had been followed up for several years prior to the
onset of his first neurological symptoms in a neuro-
ophthalmology clinic.Materials and methods
Patient and pathological material
Brain donors at the Queen Square Brain Bank for Neuro-
logical Disorders (QSBB), including the present case,
register for a brain donor program approved by a London
Multi-Centre Research Ethics Committee and tissue is
stored for research under a license from the Human
Tissue Authority. A written and signed consent for the
publication of this case report was obtained from the
patient’s wife.
Tissue blocks were taken using standard protocols.
Established pathological diagnostic criteria for CTE [5]
and PSP [8-10,16] were used. Haematoxylin and eosin
(H&E) were used to assess neuronal loss and gliosis in
the basal ganglia and substantia nigra (SN). Bielschowsky’s
silver staining was used to detect neurofibrillary tangle
and neuritic plaque pathology. Immunohistochemistry
with antibodies to phosphorylated tau (AT8), 3R tau andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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binding protein-43 (TDP-43) was performed using a
standard avidin-biotin method. The neuropathological
findings were reviewed by 2 neuropathologists (TR, JLH).
Genetic analysis
Genomic DNA was extracted from frozen brain tissue of
the index case and from the plasma sample of his older
brother, who developed corticobasal syndrome, following
informed consent. Sanger sequencing was performed
using standard procedures as previously described [17]
for LRRK2 (exons 24, 25, 27, 29, 31, 35, 36, 41 and 48),
MAPT (exons 1-13) and Progranulin (GRN) (exons 1-13).
MAPT haplotypes were determined [18]. APOƐ genotype
was determined [19]. Larger genomic rearrangements in
LRRK2 were assessed through the Multiplex Ligation-
dependent Probe Amplification (MLPA) kit P052C (MRC
Holland) [20]. C9orf72 repeat expansion was analyzed
using the reversed-prime PCR method [21].
Case presentation
At age 64, the patient developed sudden onset horizontal
double vision which was diagnosed as a right micro-
vascular ischaemic sixth nerve palsy and his blood pres-
sure was noted to be 190/110. Diabetes mellitus was
excluded. Antihypertensive medications were prescribed
and his diplopia almost completely resolved. In the fol-
lowing year, he had a further episode of sudden onset
horizontal diplopia caused by a left lateral rectus paresis
which persisted for five months with again a good recov-
ery apart from occasional double vision on looking into
the distance which improved with prism glasses. A diag-
nosis of recurrent microvascular ischaemic sixth nerve
palsy was made. Ocular examination revealed esotropia
for distance and exophoria for near vision. There was
very mild underaction of the right lateral rectus muscle.
In addition, slow vertical saccades were noted and very
mild unsteadiness in tandem walking was observed.
Magnetic resonance imaging (MRI) of the brain showed
mild periventricular white matter changes compatible
with small vessel disease. The unexpected finding of
slow vertical saccades was considered as a possible sign
of early PSP and the patient was then followed annually
at Moorfields Eye Hospital.
At age 69, the patient began to fall backwards, devel-
oped hypophonia, mild swallowing difficulties with pool-
ing of saliva and had progressive difficulty moving his
eyes up and down. Examination showed poor conver-
gence, slow vertical saccades and mild postural instabil-
ity with retropulsion on pull test. In his early 70’s, he
developed memory impairment. He also had increasing
hearing difficulties and a neuro-otological review identi-
fied a significant right canal paresis on caloric testing in-
dicative of a right peripheral vestibular dysfunction andpure tone audiometry confirmed bilateral moderate to
severe gently sloping sensorineural hearing loss. He was
referred for vestibular rehabilitation and prescribed hear-
ing aids.
At age 73, he scored 25 out of 30 on MMSE; losing 1
point on recall, 3 points on attention span and 1 point
on repetition. Full neuropsychological examination re-
vealed executive inefficiency and cognitive slowness indi-
cative of mild anterior and subcortical dysfunction. He
had facial hypomimia with frontalis overactivity, dysarth-
ria and postural instability. Eye movement examination
revealed an esotropia for near and distance and slow
hypometric vertical saccades especially on downgaze.
Vertical eye movements were full on oculocephalic test-
ing. Square wave jerks intruded on fixation and horizon-
tal smooth pursuit was saccadic. His jaw jerk was brisk
and tongue movements were slow and spastic. Haemato-
logical and biochemical blood tests and cerebrospinal
fluid study, including Whipple’s PCR, were all normal.
Genetic testing for spinocerebellar ataxia (SCA) 2, 3 and
6 and common mitochondrial (mtDNA) mutations was
negative. Repeat MRI of the brain (Figure 1) showed
generalized volume loss especially in the midbrain with
distinct tegmental atrophy in addition to the scattered
foci of abnormal signal in the white matter observed in
the previous scan. Dopamine transporter scan, [123I]FP-
CIT SPECT, showed bilateral reduced tracer uptake in
the striatum (Figure 2).
The patient became progressively more withdrawn and
was falling more frequently in the backward direction
and required a frame to mobilise. At age 74, examination
revealed absence of convergence and total loss of vertical
eye movements. There were marked hypophonia, axial
rigidity, mild retrocollis and presence of frontal release
signs. He could no longer communicate, he developed
severe dysphagia with aspiration and started losing
weight and required help with all his daily activities. He
died of right lobar pneumonia at age 75.
Of relevance in the clinical history was that he had
begun amateur boxing in his teenage years and he boxed
professionally in the heavyweight category between the
ages of 20 and 30. During his professional boxing career,
he undertook 31 fights, including 16 wins, 1 draw, and
14 defeats, 13 of which were lost by knockout. After re-
tiring from boxing, he worked as a boxing trainer for a
number of years. At the age of 65, he was diagnosed
with hypertension and hyperlipidaemia. He never
smoked and only drank alcohol occasionally. His father,
who also boxed as an amateur, died of a dementing ill-
ness aged 86 and his mother died of cerebrovascular dis-
ease aged 67. His identical twin brother also boxed
professionally for 17 years and had 55 fights, including
40 wins, 1 draw, and 14 defeats, 8 of which were lost by
knockout. The twin brother died at the age of 76 without
Figure 1 Axial T2, coronal FLAIR and sagittal T1 brain magnetic resonance images when the patient was 72 years old. Generalised
volume loss with distinct midbrain tegmental atrophy is noted. There are scattered white matter foci of abnormal signal in keeping with small
vessel disease.
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boxing or any other neurological disease. His older
brother, who has never boxed and is now aged 82, had a
two-year history of progressive limb apraxia and apraxia
of speech. He was reviewed by the author (HL) and the
diagnosis of corticobasal syndrome was made (Figure 3).
Neuropathological findings
The whole brain weight was 1311 grams. Mild dilatation
of the frontal horn of the lateral ventricle and mild re-
duction in bulk of white matter of the frontal lobe wereFigure 2 Abnormal DAT-SPECT. [123I]FP-CIT SPECT images showed bilate
nigrostriatal degeneration.noted. The major macroscopic findings were mild reduc-
tion in bulk of the globus pallidus and subthalamic nu-
cleus with pallor of the substantia nigra, reduction in
height of the midbrain and pontine tegmenta and blur-
ring of the dentate nucleus. The corpus callosum, thal-
amus, hypothalamus and mammillary body appeared
normal. The septum pellucidum was torn due to post-
mortem artefact but cavum septum pellucidum was not
apparent.
Histological examination showed severe neuronal loss
in the substantia nigra (SN) pars compacta. There wasral and symmetrical reduced tracer uptake in the striatum indicative of
Figure 3 Family tree. The arrow indicates the index patient. Filled symbols represent affected family members. Red triangles indicate family
members in whom sequencings of MAPT, Progranulin, LRRK2 and C9orf72 repeat expansion were negative and tau haplotype was H1/H1 and
ApoE genotype was E3/E3.
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(STN), locus coeruleus, dentate nucleus and mild Purkinje
cell depletion in the cerebellar cortex. Tau immunohisto-
chemistry revealed NFTs, pre–tangles, coiled bodies and
neuropil threads in the SN, STN, brainstem nuclei, pons,
cerebellar white matter and neocortex. Tufted astrocytes
were noted in the striatum and neocortex. Tau lesions in
the basal ganglia and brainstem were composed of 4R tau
isoforms. These features fulfilled the diagnostic criteria of
PSP (Table 1, Figure 4) [8-10,16].
In addition to these findings, there was marked loss of
pyramidal neurons in the CA1 subregion of the hippo-
campus and subiculum accompanied by frequent NFTs
and ghost tangles. Tau immunohistochemistry demon-
strated that extensive NFTs and neuropil threads were
present throughout the rest of the hippocampal formation,
including CA2, CA3 and CA4 subregions, and extending
into the fusiform gyrus. There were moderate numbers of
pre-tangles and occasional NFTs in the dentate fascia.
These NFTs contained 4R tau isoforms, whereas 3R tau
immunohistochemistry was more restricted in distribution
and was positive in NFTs in the CA1 subregion, subicu-
lum, entorhinal and transentorhinal cortices. The amyg-
dala was similarly affected by tau pathology. Ghost
tangles, representing residual NFTs lying in the neuropil
following neuronal death, were frequently observed in the
CA1 subregion and subiculum visible in H&E stained
sections and using Bielschowsky’s silver impregnation.
These were also tau and Aβ immunoreactive, the latterindicating secondary Aβ deposition on extracellular pro-
tein aggregates. In neocortical regions foci of subpial tau-
positive astrocytic tangles were observed, typically in the
depths of sulci and occasionally with a perivascular distri-
bution within the cortex. Moderate superficial NFTs in
the temporal cortex were noted. These findings were con-
sistent with coexisting chronic traumatic encephalopathy
(CTE) pathology (Table 2, Figure 5) in additional to the
PSP-tau pathology described above. The distribution of
CTE pathology best corresponds to stage III according
to McKee’s proposed criteria [5], although the NFTs in
the hippocampus may partly be caused by AD-related
pathology.
TDP-43-immunoreactive neuronal cytoplasmic inclu-
sions (NCIs) and threads were identified in small num-
bers in the dentate fascia, entorhinal and transentorhinal
cortices with sparse threads/neurites in the amygdala,
and medullary tegmentum. TDP-43-positive neuronal
intranuclear inclusions (NIIs) were rare in the entorhinal
and transentorhinal cortices. There were no TDP-43 in-
clusions in the primary motor cortex and the XIIth cra-
nial nerve nucleus. The spinal cord was not available for
examination.
Aβ immunohistochemistry demonstrated parenchymal
deposition in the neocortex where there were modereate
numbers of diffuse deposits with sparse neuritic plaques
and also in the hippocampus and striatum correspond-
ing to Thal phase 3 [22]. The distribution of tau path-
ology could be considered to correspond to Braak and
Table 1 Distribution of immunoreactive inclusions positive to AT8 and TDP antibodies
Tau-immunoreactive lesions TDP-43-immunoreative
lesions
Neuritic
plaques
NFTs & PreTs Coiled
bodies
Neuropil
threads
Tufted
astrocytes
Perivascular
astrocytic
tangles
Subpial
astrocytic
tangles
NCIs NIIs Threads
Anterior frontal + ++ ++ ++ + + ++ - - -
Parietal + + ++ ++ + + + - - -
Temporal cortex + + + ++ + - ++ - - -
Hippocampus - +++ + +++ - - + + + +
Amygdala - +++ - +++ - + NA - - +
Caudate - + + +++ ++ + NA - - -
Putamen - + + + + - NA - - -
Globus pallidus - + ++ + - - NA - - -
Internal capsule - NA ++ +++ - - NA - - -
STN - ++ ++ +++ - - NA
Substantia nigra - ++ ++ +++ - - NA - - -
Red nucleus - ++ +++ +++ - - NA - - -
Oculomotor nucleus - ++ - +++ - - NA - - -
Pons-tegmentum - ++ +++ +++ - - NA
Pons-base - ++ + +++ - - -
Locus ceruleus - +++ + +++ - - NA
Medullary tegmentum - ++ +++ +++ - - + + - +
Inferior olive - ++ + ++ - - -
Dentate nucleus - ++ - ++ - - NA
Cerebellar wm - ++ NA ++ - - -
(-) none; (+) sparse; (++) moderate; (+++) frequent, NA-not applicable; blank spaces indicate that immunohistochemistry staining was not performed in the
corresponding region; 3R: 3-repeat tau isoform; 4R: 4-repeat tau isoform: Aβ: amyloid beta; AT8: phosphorylated tau; NCIs: neuronal cytoplasmic inclusions; NFTs:
neurofibrillary tangles, NIIs: neuronal intranuclear inclusions; preTs: pretangles; STN: subthalamic nuclei; wm: white matter.
Ling et al. Acta Neuropathologica Communications 2014, 2:24 Page 5 of 11
http://www.actaneurocomms.org/content/2/1/24Braak stage III [23]. These changes corresponded to an
‘intermediate’ level of AD pathologic change (A2, B2,
C1) according to the 2012 NIA-Alzheimer Association
guidelines [24].
Mild small vessel disease was evidenced by the find-
ings of hyaline mural thickening of the blood vessels in
the subcortical white matter. There were no Lewy bodies,
cerebral amyloid angiopathy, argyrophilic grains, or p62-
positive ‘star-shaped’ inclusions in the hippocampus or
small ‘dot-like’ structures in the cerebellar granule cells of
the type associated with C9ORF72 repeat expansion.
In summary, the neuropathological diagnoses of this
case were 1) PSP, 2) CTE stage III, 3) limbic TDP-43
proteinopathy, 4) intermediate level of AD pathologic
change and 5) mild small vessel disease.
Genetic findings
The MAPT haplotype of this patient was H1/H1 and
APOE genotype was E3/E3. LRRK2, MAPT, progranulin
sequencings and C9orf72 repeat expansions were all
negative. No large genomic rearrangements in LRRK2were detected. The genetic findings of the older brother
who has developed corticobasal syndrome were similarly
negative.
Discussion
We report the case of a professional boxer who visited a
neuro-ophthalmology clinic following the development
of bilateral sequential lateral rectus palsy in his 60’s due to
microvascular ischaemic insults. Neuro-ophthalmological
review at the time led to detection of slow vertical sac-
cades, which were considered to be the harbinger of an
unrelated neurodegenerative disease. A few years later the
patient experienced postural instability and backward falls
along with progressive onset of other clinical features
highly suggestive of Richardson’s syndrome (RS), the clas-
sical presentation of PSP [14]. The neuroimaging findings
of midbrain atrophy and reduced striatal tracer uptake on
dopamine transporter scan were also supportive of the
clinical diagnosis of PSP [25]. Post-mortem examination
confirmed the neuropathological findings of both PSP
and CTE. The concomitant CTE-tau pathology in the
Figure 4 Illustrations of the substantia nigra (SN) and progressive supranuclear palsy (PSP) pathology. There is severe neuronal loss and
gliosis (A) with neurofibrillary tangles (NFTs) (white arrow, B) in the SN. Tau immunohistochemistry demonstrates pre-tangles (PreT, black arrow,
C) and occasional tufted astrocytes (TAs) in the motor cortex (D), and coiled bodies (CBs, arrowheads, E) in the posterior frontal cortical white
matter, NFTs and neuropil threads (NTs) in the pontine base (F) and PreTs (black arrow, G), NFTs (white arrow, G) and threads in the dentate
nucleus (G), CBs and fine NTs in the cerebellar white matter (H), and, TAs in the caudate nucleus (I, J). TAs in the motor cortex (F) and caudate
(J) are stained positive using 4-repeat tau antibody but not 3-repeat tau antibody. A: H&E, B, C,-E, G-I: tau immunohistochemistry (AT8), F & J: 4-repeat
tau immunohistochemistry. Bar in J = 50 μm in A-C, E, G, H = 25 μm in D, I, J and = 100 μm in F.
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cline. Clinical presentations of CTE in older individuals
may be indistinguishable from AD with episodic memory
impairment and executive dysfunction being more com-
mon than behavioural or mood changes [26].
Asymptomatic CTE can be observed in 11% of all
CTE cases and is associated with early CTE pathology
[5]. Moreover, there have been no pathologically con-
firmed CTE cases that present with a PSP-RS phenotypereported in the literature. Ocular abnormalities can be
observed in CTE but their characteristics are not well
defined [27]. The cognitive and behavioural symptoms
and motor impairments in CTE can sometimes mimic
other neurodegenerative disorders such as AD, fronto-
temporal dementia or Parkinson’s disease. Nevertheless,
CTE tends to progress relatively slowly with a disease
course spanning over three to four decades [5,27-29].
Cognitive impairments in our patient were consistent
Table 2 Differentiating pathological and biochemical features between PSP and CTE
Pathological features PSP CTE
Tau protein isoform profile -4-repeat predominant tau -Both 4- and 3-repeat tau
-4-repeat predominant astrocytic tangles in subpial and
periventricular regions
Characteristic features -Neuronal (NFTs, neuropil threads) and glial pathology
(tufted astrocytes, coiled bodies) in a typical distribution
-Perivascular NFTs locate at depths of sulci and in
superficial cortical layers
-Neuronal loss in STN and dentate nucleus -Subpial, perivascular and periventricular astrocytic tangles
-Relatively mild Aβ pathology
-Ghost tangles in limbic region and temporal neocortex
Shared features -Associated TDP-43 related pathology limited to
limbic region
-TDP-43 pathology in CTE tends to be more widespread
involving cortical region in stage III and IV
-Neuronal loss in SN and LC -Neuronal loss in SN and LC
Distribution of
hyperphosphorylated
tau pathology
-SN, STN, GP, pons -Cortical regions including frontal cortex, medial temporal
lobe, thalamus and brainstem
-Striatum, oculomotor complex, medulla, dentate
nucleus, inferior olive and neocortex
CTE: chronic traumatic encephalopathy, GP: globus pallidus, LC: locus ceruleus, NFT: neurofibrillary tangle, PSP: progressive supranuclear palsy, SN: substantia
nigra, STN: subthalamic nucleus.
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experienced any behavioral changes or neuropsychiatric
symptoms that would have suggested early presentation of
CTE prior to the onset of his diplopia. Cavum septum pel-
lucidum or septal fenestrations, markers of head trauma,
were absent in this case [29].
Repetitive head injury is the only known definitive risk
factor for CTE but not all individuals who were exposed
to repetitive head injury develop CTE [27]. A prospect-
ive study found that 68 out of 85 (80%) participants with
histories of repetitive head injury had CTE pathology
[5]. Apo E4 allele, which increases the risk of developing
AD, has been linked with poor long-term neurological
outcome after severe traumatic brain injury [30] and
more severe CTE-related neurological deficits in boxers
[31]. However, more studies are required to confirm
Apo E4 as a susceptibility allele for CTE. Notably, this
patient carried Apo E3/E3, the most common genotype
in the population, may have had a protective effect from
severe CTE-related neurological deficits [32]. Other pu-
tative risk factors for CTE, which were also observed in
our patient, including family history of dementia, profes-
sional rather than amateur boxing, head trauma during
youth and prolonged exposure will require further verifi-
cation [27].
Head trauma is a known risk factor for certain neuro-
degenerative conditions such as AD [33], amyotrophic
lateral sclerosis (ALS) [34] and Parkinson’s disease [35],
but has never been firmly linked with PSP [36]. It is pos-
sible that our patient had subclinical CTE and subse-
quently developed another tauopathy, PSP, in later life
by chance. However, a recent large clinicopathological
series revealed that over a third of CTE cases had co-
morbid neurodegenerative diseases; of the 68 CTE casesstudied, 11 had Lewy body diseases, 8 had motor neuron
disease, 7 had AD, 2 had FTLD-TDP, 1 had Pick’s disease
and 1 had PSP [5]. The latter case had stage II CTE and
concomitant PSP pathologies and died in his 70’s [5],
but the clinical features were not elaborated. Another
prevalence study identified one case of PSP among 704
retired Thai boxers [37]. It is plausible that either the
CTE-tau pathology triggers the molecular pathways
resulting in the accumulation of PSP-tau pathology in
later life or both CTE and PSP share common risk fac-
tors, notably head trauma and axonal injury [28,38]. Fur-
ther studies are required to establish any causative
relationship between mild head injury and PSP.
The family history of this patient was intriguing. His
identical twin brother, who would have also carried the
potentially protective Apo E3/E3 alleles, had a long pro-
fessional boxing career but never developed any neuro-
logical or psychological sequelae. The patient’s older
brother had a progressive neurodegenerative disorder
compatible with corticobasal syndrome. The underlying
pathologies of corticobasal syndrome are heterogeneous,
the most common of which are PSP, AD, FTLD and cor-
ticobasal degeneration (CBD) [39]. In both PSP and CBD,
the possession of H1 allele of the MAPT gene and, in
particular, the H1/H1 genotype is a risk factor which
was also detected in both the patient and his older
brother [40,41]. Although PSP and CBD are sporadic
conditions, there have been reports of familial aggrega-
tion of parkinsonism in PSP [42] and a recent genome-
wide association study (GWAS) identified variants
within several loci increasing the risk for PSP [43]. Inter-
estingly, Apo E4 allele frequency is lower in PSP than in
controls [43,44]. All other gene sequencings, including
LRRK2,MAPT, progranulin and C9orf72 repeat expansions,
Figure 5 Illustrations of chronic traumatic encephalopathy (CTE) pathology. Tau immunohistochemistry demonstrates subpial astrocytic
tangles in the depth of sulci of the frontal cortex (A), perivascular astrocytic tangles in the insula (B) and parietal cortices (C) and neurofibrillary
tangles (NFTs) are occasionally observed in the perivascular region (white arrow, B). There is marked neuronal loss with ghost tangles (arrowhead)
and NFTs (arrow) in the CA1 hippocampal subregion on H&E (D) and amyloid-β deposition on the ghost tangles can be observed (inset in D).
TDP-43 immunohistochemistry shows occasional neuronal cytoplasmic inclusions (NCIs) in the dentate fascia of the hippocampus (E), a neuronal
intranuclear inclusion (NII) in the entorhinal cortex (F), and, occasional NCIs and threads in the CA1 hippocampal subregion (G). Extensive tau-
immunoreactive NFTs and neuropil threads (NTs) are observed in CA1 (H) and throughout the hippocampal formation and these NFTs and NTs
are stained positive using either 3-repeat (I) and 4-repeat tau antibodies (J). A, B, C, H: tau immunohistochemistry (AT8), D: H&E, Inset in D: Aβ
immunohistochemistry, E-G: TDP-43 immunohistochemistry, I: 3-repeat, and J: 4-repeat tau immunohistochemistry. Bar in J = 50 μm in A, H-J, = 100 μm
in B and = 25 μm in D-G.
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ing there was no known, common/conventional monogen-
etic cause to their neurological conditions. There have
been two previous reports on familial PSP/CBD with histo-
pathological confirmation; MAPT sequencing was negative
in the affected family members in both families and, in the
more recent series, progranulin sequencing was also
negative [45,46]. Future genetic analysis on CTE cases
with co-existing neurodegenerative conditions and exome
sequencings on the familial CBD/PSP cases are warranted.TDP-43 is a major disease protein in FTLD and ALS
and is occasionally observed in Lewy body disorders and
tauopathies such as CTE and PSP [6,47-50]. TDP-43
pathology tends to localise in the limbic system when it
co-exists in other neurodegenerative disorders; with an
exception of advanced stages of CTE (stages III and IV),
where TDP-43 pathology may be widespread involving
the cortices, medial temporal lobe and brainstem in
most cases [6]. In a subset of CTE cases, TDP-43 posi-
tive inclusions and neurites are found in the anterior
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with corticospinal tract degeneration and loss of anterior
horn cells, giving an ALS-like clinical picture [7]. TDP-
43 inclusions in our case were sparse and confined to
the limbic system [50]. TDP-43 immunoreactivity may
modify clinical features in AD and other types of demen-
tia [51] and is closely associated with hippocampal scler-
osis [51,52]. The cause and mechanism of TDP-43
inclusions in tauopathies remain elusive but it is postu-
lated that tau aggregates may promote aggregation of
TDP-43 pathology through cross-seeding [28,38]. There
is also evidence to show that the accumulation of TDP-
43 in CTE brains may be part of a physiological injury
response to traumatic brain injury [53].
Following the description of the ‘punch drunk’ symp-
tom spectrum in boxers by Martland in 1928 [1] and
motor deficits and mental confusion, termed dementia
pugilistica, by Millspaugh in 1937 [54], Corsellis et al in
1973 published the neuropathological findings of 15
boxers and concluded that dementia pugilistica was a
neuropathologically distinct disorder despite its similar-
ities to AD [29]. The NFTs in CTE and AD are bio-
chemically the same, containing both 3R and 4R tau
[55]. However, tau pathologies in CTE tend to cluster
around blood vessels, locate in the depths of the sulci
and in the superficial cortical layers, are patchy and ir-
regularly distributed and Aβ deposits are relatively
scanty [4,56,57]. These pathological features were used
in our case to distinguish CTE pathology from
Alzheimer-related tau pathology, although overlaps can
occur in the hippocampus and temporal neocortex. The
clustering of astrocytic tangles in the subpial and peri-
vascular regions in CTE, as observed in this case, is
topographically distinct from thorny astrocytes in the
medial temporal lobe reported in ageing and AD
(Figure 5) [27]. In CTE stages III and IV, the loss of pig-
mented neurons in SN and locus coeruleus is common,
which can overlap with PSP pathology, however the
STN tends to be preserved in CTE but not in PSP [5,9].
In slowly progressive tauopathies such as CTE and post-
encephalitic parkinsonism, ghost tangles are formed as a
result of neuronal death and the formation of extracellu-
lar NFTs and can be observed in the limbic system and
the temporal neocortex with evidence of Aβ deposition
as in our case (Figure 5) [58,59].
Conclusion
We illustrate the case of a former boxer who had been a
clinical and pathological diagnostic challenge. His clin-
ical and post-mortem diagnoses were consistent with
classical PSP. However, his bilateral sequential lateral
rectus palsy, peripheral vestibular dysfunction and long
history of repetitive head injury during his boxing career
were red herrings that had complicated the clinicalpicture. Pathologically, it had also been a challenge to
dissect the concomitant PSP, CTE and AD-related tau
pathologies.
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